
Photo of Uma Borate from www.na.eventscloud.com
Apr 8, 2024, 15:14
Uma Borate: Should luspatercept be used as front-line therapy in RS- low-risk transfusion-dependent MDS?
Uma Borate, Acute Leukemia Translation Lead, Associate Professor at OHSU, shared on X:
“Fantastic start to ALFlive24 at Medscape LIVE with a clinically relevant debate amongst the greatest minds in MDS Rami Komrokji and Guillermo Garcia-Manero– Should luspatercept be used as front-line therapy in RS- low-risk transfusion-dependent MDS? What do you think ?- Vote”
Source: Uma Borate/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 15:06
Feb 21, 2025, 14:27
Feb 21, 2025, 14:13
Feb 21, 2025, 13:29